US FDA approves Sanofi's bleeding disorder therapy
The U.S. Food and Drug Administration approved French drugmaker Sanofi's hemophilia therapy, introducing a new type of ...
Fierce Pharma1d
Sanofi's versatile Qfitlia scores FDA nod to enter crowded hemophilia market
Over the last three years, the FDA has approved six new hemophilia drugs, including three gene therapies. | Over the last ...
Endpoints News1d
FDA ap­proves Sanofi's RNAi drug for he­mo­phil­ia A and B
FDA approves Sanofi's RNAi hemophilia drug fitusiran, licensed from Alnylam, to treat both hemophilia A and B by lowering ...
Sanofi’s Easier to Use Hemophilia Drug Approved by US FDA
Sanofi’s treatment for hemophilia that can be administered as infrequently as once every other month, was approved by the US ...
FDA approves Sanofi treatment for hemophilia A or B
The U.S. Food and Drug Administration approved Qfitlia for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult ...
AbbVie Vs. Sanofi: Which Is The Better Investment Right Now
Discover whether AbbVie or Sanofi holds the edge in the global immunology market and find out which stock shows more ...
China’s Xi urges foreign firms to resist ‘acts that turn back the wheel of history’
Xi meets with business reps as China takes aim at unilateralism and protectionism while ramping up a charm offensive for foreign investors against the backdrop of two global conferences In a ...
Analysts Set Sanofi (NASDAQ:SNY) PT at $60.00
Sanofi (NASDAQ:SNY – Get Free Report) has been assigned an average recommendation of “Buy” from the five analysts that are currently covering the stock, Marketbeat Ratings reports. Two research ...
Sanofi Chlamydia vaccine candidate granted fast track designation by the US FDA
Chlamydia vaccine candidate granted fast track designation by the US FDA Chlamydia infection can contribute to pelvic inflammatory diseases in women, which can lead to pregnancy complications or infer ...
Sanofi reports tolebrutinib submission accepted for FDA priority review
The U.S. Food and Drug Administration is evaluating under priority review the regulatory submission of tolebrutinib to treat non-relapsing ...
Zacks Investment Research on MSN4d
FDA Accepts Sanofi's Filing for Multiple Sclerosis Drug Tolebrutinib
Sanofi SNY announced that the FDA has accepted its regulatory filing seeking approval for its investigational BTK inhibitor ...
Rolls-Royce CEO fired managers and held staff brainstorms as part of a ‘4 pillar’ turnaround plan that led to 500% share price jump
Tufan Erginbilgiç's four pillars involved showing employees the extent of Rolls-Royce's issues, then giving them a say in ...